RheumaCast dives into the latest developments in rheumatology, offering in-depth discussions on research, clinical advances, and expert comments. Each episode sheds light on significant publications, upcoming events, and evolving trends in the field. Perfect for rheumatologists, healthcare professionals, and researchers eager to stay at the forefront of rheumatology.
Subclinical Psoriatic Arthritis: Does it Really Exist?
In this episode of RheumaCast, we discuss the evolving concept of subclinical psoriatic arthritis and the challenges associated with its definition and clinical relevance.
The episode explores current frameworks describing the transition from psoriasis to psoriatic arthritis, highlighting the limitations of existing definitions, particularly the reliance on arthralgia and imaging findings in the absence of clinical synovitis.
A central theme is the risk of misclassification and overtreatment, given the lack of validated biomarkers, the heterogeneity of psoriatic disease, and the limited specificity of imaging abnormalities. The discussion also draws parallels with preclinical rheumatoid arthritis, emphasizing both opportunities and pitfalls of early intervention strategies.
Finally, we address key research priorities, including longitudinal psoriasis cohorts, advanced imaging approaches, and multiomic biomarker development, with the goal of improving risk stratification and enabling targeted prevention while avoiding overdiagnosis.
This episode is based on publication Kharouf F, et al. Ann Rheum Dis 2026, doi: 10.1016/j.ard.2026.03.011, and developed with NotebookLM.
22 Mar 2026
What is the relevance of structural damage in psoriatic arthritis?
In this episode of RheumaCast, we discuss the functional consequences of structural joint damage in psoriatic arthritis based on data from a large, prospectively followed cohort.
While inflammation is often considered the main driver of impaired physical function, this study provides a more nuanced view. Radiographic damage, particularly severe joint destruction, shows an independent association with functional impairment—even after adjusting for disease activity and other confounders. Importantly, not all damage is equal: mild or moderate changes appear to have limited functional impact, whereas complete joint destruction demonstrates a clear and clinically meaningful effect, with a dose–response relationship.
We also explore how these findings should influence treatment strategies, emphasizing early intervention and prevention of irreversible damage rather than relying solely on control of inflammatory activity.
This episode places structural damage into context and highlights its relevance for long-term patient outcomes in PsA.
This episode is based on publication Mehta P, et al. Arthritis Rheumatol 2026; doi:10.1002/art.70145
and developed with NotebookLM.
24 Dec 2025
Do we need new therapies in spondyloarthritis?
Industry experts discuss the challenges in achieving remission for axial spondyloarthritis patients, highlighting diagnostic inaccuracies and non-inflammatory pain mechanisms, while exploring emerging therapeutic concepts for improved patient outcomes.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
5.0 / 5
3 ratings
Contact RheumaCast
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of RheumaCast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
